Jennifer Kim
Stock Analyst at Cantor Fitzgerald
(3.29)
# 1,020
Out of 4,944 analysts
35
Total ratings
57.14%
Success rate
12.97%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Jennifer Kim
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| BLTE Belite Bio | Reiterates: Overweight | n/a | $72.23 | - | 5 | May 15, 2025 | |
| PGEN Precigen | Reiterates: Overweight | n/a | $1.91 | - | 4 | May 15, 2025 | |
| INSM Insmed | Reiterates: Overweight | n/a | $122.87 | - | 8 | Feb 20, 2025 | |
| FBIO Fortress Biotech | Reiterates: Overweight | n/a | $1.93 | - | 4 | Jun 20, 2024 | |
| EYPT EyePoint Pharmaceuticals | Reiterates: Overweight | n/a | $11.01 | - | 6 | Jun 20, 2024 | |
| OCGN Ocugen | Maintains: Overweight | $2.5 → $2 | $1.03 | +94.17% | 2 | Aug 31, 2023 | |
| LPCN Lipocine | Reiterates: Overweight | $33 | $3.02 | +994.53% | 2 | Jul 27, 2023 | |
| PRQR ProQR Therapeutics | Maintains: Overweight | $5 → $4.5 | $2.02 | +122.77% | 2 | May 17, 2023 | |
| AYTU Aytu BioPharma | Maintains: Overweight | $220 → $100 | $2.29 | +4,266.81% | 2 | May 17, 2022 |
Belite Bio
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $72.23
Upside: -
Precigen
May 15, 2025
Reiterates: Overweight
Price Target: n/a
Current: $1.91
Upside: -
Insmed
Feb 20, 2025
Reiterates: Overweight
Price Target: n/a
Current: $122.87
Upside: -
Fortress Biotech
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $1.93
Upside: -
EyePoint Pharmaceuticals
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $11.01
Upside: -
Ocugen
Aug 31, 2023
Maintains: Overweight
Price Target: $2.5 → $2
Current: $1.03
Upside: +94.17%
Lipocine
Jul 27, 2023
Reiterates: Overweight
Price Target: $33
Current: $3.02
Upside: +994.53%
ProQR Therapeutics
May 17, 2023
Maintains: Overweight
Price Target: $5 → $4.5
Current: $2.02
Upside: +122.77%
Aytu BioPharma
May 17, 2022
Maintains: Overweight
Price Target: $220 → $100
Current: $2.29
Upside: +4,266.81%